Takahari, Daisuke http://orcid.org/0000-0002-2492-6014
,
Ito, Seiji
Mizusawa, Junki
Katayama, Hiroshi
Terashima, Masanori
Sasako, Mitsuru
Morita, Shinji
Nomura, Takashi
Yamada, Makoto
Fujiwara, Yoshiyuki
Kimura, Yutaka
Ikeda, Atsuki
Kadokawa, Yoshio
Sano, Takeshi
Article History
Received: 10 June 2019
Accepted: 2 September 2019
First Online: 12 September 2019
Compliance with ethical standards
:
: Daisuke Takahari reports grants and personal fees from Taiho Pharmaceutical Co. and Ono Pharmaceutical Co., and personal fees from Eli Lilly Japan, Bristol-Myers Squibb, Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Ltd., outside the submitted work. Seiji Ito reports grants from National Cancer Center, Japan, Ministry of Health, Labour and Welfare, Japan, during the conduct of the study, grants and personal fees from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., personal fees from Taiho Pharmaceutical Co., grants from Merck Sharp and Dohme, outside the submitted work. Junki Mizusawa reports grants from Ministry of Health, Labour and Welfare, Japan, Japan Agency for Medical Research and Development (AMED), during the conduct of the study. Hiroshi Katayama reports grants from Ministry of Health, Labour and Welfare, Japan, AMED, during the conduct of the study; personal fees from Johnson & Johnson, outside the submitted work. Masanori Terashima reports personal fees from Taiho Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Bristol-Myers Squibb, Yakult Honsha Co., Ltd., Takeda Pharmaceutical Company Ltd., Eli Lilly Japan, Daiichi Sankyo, outside the submitted work. Mitsuru Sasako reports grants from Japanese Government, personal fees from Taiho Pharmaceutical Co, Sanofi Aventis, during the conduct of the study; grants from Japanese Goverment, personal fees from Chugai Pharmaceutical Co., Taiho Pharmaceutical Co., Yakult Honsha Co., Ltd., Sanofi Aventis, Eli Lilly Japan, Merck Sharp and Dohme Japan, outside the submitted work. Takeshi Sano received personal fees from Taiho Pharmaceutical Co. during the conduct of the study and has received personal fees from Chugai Pharmaceutical Co, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Ono Pharmaceutical Co., Eli Lilly Japan, Ethicon, Covidien, Olympus, outside of the submitted work. Shinji Morita, Takashi Nomura, Makoto Yamada, Yoshiyuki Fujiwara, Yutaka Kimura, Atsuki Ikeda, and Yoshio Kadokawa have no conflicts of interest to disclose.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or an appropriate substitute for it was obtained from all patients for their inclusion in this study.
Free to read: This content has been made available to all.